Th2 and Th22 activation induce the acute phase of AD and show a progressive intensification to the chronic phase (Gittler et al., 2012), while IL-17 sees a decrease in the progression (Souwer et al., 2010), lower levels of IL-17 during the chronic phase of AD indicate a possible Th17-to-Th1 shift in later phases of the disease (Cesare et al., 2008; Koga et al., 2008). This evidence concerns the gene IL17A and Alzheimer disease.